Analysts Say Medline Has The Secret Sauce For Sustained Growth

Benzinga_recent_news01-13

Several analysts initiated coverage on Medline Inc. (NASDAQ:MDLN) on Monday, one of the largest providers of medical-surgical products and supply chain solutions. Its product portfolio includes ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603528796?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/12/Stuttgart--Germany---03-07-2025-Smartpho.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-13 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603528796","market":"sh","top_or_hot":-1,"title":"Analysts Say Medline Has The Secret Sauce For Sustained Growth","media":"Benzinga_recent_news","content":"<div>\n<p>Several analysts initiated coverage on Medline Inc. (NASDAQ:MDLN) on Monday, one of the largest providers of medical-surgical products and supply chain solutions.\nIts product portfolio includes ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/26/01/49855796/analysts-say-medline-has-the-secret-sauce-for-sustained-growth\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts Say Medline Has The Secret Sauce For Sustained Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts Say Medline Has The Secret Sauce For Sustained Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 02:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/initiation/26/01/49855796/analysts-say-medline-has-the-secret-sauce-for-sustained-growth><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Several analysts initiated coverage on Medline Inc. (NASDAQ:MDLN) on Monday, one of the largest providers of medical-surgical products and supply chain solutions.\nIts product portfolio includes ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/26/01/49855796/analysts-say-medline-has-the-secret-sauce-for-sustained-growth\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDLN","symbol_name":"Medline Inc","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/01/49855796/analysts-say-medline-has-the-secret-sauce-for-sustained-growth","article_id":"2603528796","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/12/Stuttgart--Germany---03-07-2025-Smartpho.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/01/49855796/analysts-say-medline-has-the-secret-sauce-for-sustained-growth","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603528796","pubTimestamp":1768244340,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Medline received favorable coverage from several analysts. It recently raised $7 billion in an IPO and has a strong product portfolio.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDLN":"Medline Inc","BK4198":"医疗保健用品"},"translate_title":"分析师称Medline拥有持续增长的秘方","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDLN":1.5},"content_text":"Several analysts initiated coverage on Medline Inc. (NASDAQ:MDLN) on Monday, one of the largest providers of medical-surgical products and supply chain solutions.\nIts product portfolio includes surgical kits, wheelchairs, crutches, hospital beds, fluid delivery sets, syringes, and pressure monitoring lines, among others.\nIn December 2025, Medline closed its upsized initial public offering of 248.44 million shares at $29.00 per share, raising over $7 billion.\nReuters noted that the Medline IPO was the biggest globally ‌in 2025.\nAs per data from Benzinga Pro, Medline commands a market capitalization of around $32 billion.  \nBank of America Securities initiated coverage of Medline with a Buy rating and a $50 price forecast, implying 23% potential upside. Analyst Andrew Obin said Medline is the U.S. market leader in the manufacturing and distribution of medical-surgical products.\n“We think the company will deliver sustainable high-single digit organic growth on market share gains and strong med-surg demand. We see upside to estimates from potential M&A,” Obin wrote on Monday.\nBTIG initiated Medline with a Buy rating and a price forecast of $50. “We view Medline as being the ‘gold standard’ for logistics and supply chain services,” wrote analyst David Larsen.\nAnalyst Larsen said that stable pricing and disciplined execution have enabled Medline to gain and expand market share in a $375 billion total addressable market, including $175 billion in the U.S. He expects 2025 revenue growth of 11% year over year, outpacing many competitors.\nRBC Capital Markets initiated with an Outperform rating and a price forecast of $47.\nAnalyst Ryan Halsted wrote, “We believe MDLN is poised to leverage their unique vertically integrated business model during a time of underlying macro tailwinds…”\nThe analyst also noted that IPO proceeds, after paying down $4 billion in debt, provide Medline with ~$1 billion in dry powder, which could be deployed either for M&A or international market expansion, which is additive to Medline’s high single-digit organic topline growth.\nPiper Sandler initiated with an Overweight rating and a price target of $50.\nAnalyst Jason Bednar said, “MDLN’s Prime Vendor strategy is the secret sauce, the crucial element that provides an avenue for sustained growth.”\nMedline’s consistent history of growth and business model differentiation provides a defensible valuation floor, Piper analyst added.\nStifel initiated with a Buy rating and a price forecast of $46.\nAnalyst Rick Wise on Monday wrote, “Medline’s high-single-digit or better sales growth outlook is strongly underpinned by the company’s success in annually winning new prime vendor relationships.”\nAnalyst Wise added that Medline is the largest pureplay publicly-traded MedSurg product & distribution company, with a 58-year consistent annual growth track record and a unique business model.\nTD Cowen initiated with a Buy rating and a price target of $46.\n“We believe Medline, the leading med-surg distributor/manufacturer, can continue to take market share, see margin expansion from conversion to branded products, and grow from M&A/entering new markets.”\nMedline’s combined portfolio breadth and low product costs have allowed it to take significant market share from competitors.\nAnalyst Charles Rhyee added that tariffs are a large but manageable risk.\nMDLN Price Action: Medline shares were up 3.44% at $41.91 at the time of publication on Monday, according to Benzinga Pro data.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603528796","isCrawlerRequest":true}